companies / oculis-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 114,696,000114.7M | ○ |
|---|---|---|
| founded | 2017 | |
| hq | Lausanne, Switzerland | |
| industry | unknown | |
| stage | series-b+ |
Oculis is a clinical-stage ophthalmology company developing topical and systemic treatments for serious eye conditions including diabetic macular edema, glaucoma, and dry-eye disease. Its OCS-01 dexamethasone eye drop uses a nanoparticle platform that delivers drug into the posterior segment without injection.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-08-15 | seed | 114,480,000114.5M | null | ○ |
Cloudflare, WordPress, Google Tag Manager, GSAP 3.12.5, Cloudflare Bot Management, Cookiebot, WP Engine, WP Rocket 3.21.3, PHP, MySQL, jquery 3.7.1
| fact | status | src |
|---|---|---|
| Seed, $114.5M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |